The objective of this study is to explore the efficacy and safety of rivaroxaban @ mg once daily ( @ mg if creatinine clearance is @-@ mL/min ) compared with dose-adjusted vitamin K antagonists ( VKAs ; international normalized ratio @-@ @ ) in patients scheduled for elective cardioversion .